Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Department of Pharmacy, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
Medicine (Baltimore). 2024 Jul 26;103(30):e39049. doi: 10.1097/MD.0000000000039049.
Patients with gastric cancer show a relatively low incidence of developing secondary myelodysplastic syndrome (MDS).
A 60-year-old man was admitted because of pain and discomfort in the upper abdomen and intermittent abdominal pain.
Ulcerative moderately poorly differentiated adenocarcinoma (pT2N2M0G3, stage IIB) and MDS.
The patient underwent chemotherapy with oxaliplatin (OXP, intravenously guttae on day 1) plus capecitabine (CAP, bis in die orally on day 1-14). The patient developed degree III myelosuppression after OXP plus CAP chemotherapy and MDS was subsequently confirmed by diagnosis of the bone marrow biopsy. Temporary but significant hematological improvements were observed after the patient received corresponding treatment, which helped achieve remission and improve pancytopenia.
The patient presented partial remission after corresponding treatment and no other complications have been recorded.
Acute MDS is an unusual adverse effect induced by OXP plus CAP chemotherapy. It is urgent to suggest implementing a supplementary assessment or examination for patients receiving these therapies in future cases.
胃癌患者发生继发性骨髓增生异常综合征（MDS）的发病率相对较低。
一名 60 岁男性因上腹痛和间歇性腹痛入院。
溃疡型中分化腺癌（pT2N2M0G3，IIB 期）和 MDS。
患者接受奥沙利铂（OXP，第 1 天静脉滴注）加卡培他滨（CAP，第 1-14 天每天 2 次口服）化疗。OXP 联合 CAP 化疗后患者发生 III 级骨髓抑制，骨髓活检诊断为 MDS。患者接受相应治疗后，暂时但显著的血液学改善，帮助达到缓解并改善全血细胞减少症。
患者经相应治疗后部分缓解，未记录其他并发症。
急性 MDS 是 OXP 联合 CAP 化疗引起的不常见的不良反应。对于接受这些治疗的患者，建议在未来的病例中进行补充评估或检查。
